Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 3
A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxo…
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis PharmaceuticalsNCT07357727
Phase 3
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include pa…
Thrombocythemia, EssentialPrimary MyelofibrosisMyelofibrosis+3 more
Merck Sharp & Dohme LLCNCT06351631
Phase 1
A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacok…
Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera Myelofibrosis+3 more
Ajax Therapeutics, Inc.NCT06343805
Phase 2
A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philad…
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential Thrombocythemia+5 more
National Cancer Institute (NCI)NCT06661915